Tylenol maker rebounds day after Trump’s unfounded claims about its safety
By Michelle Chapman, business writer of the Associated Press
The actions of the Tylenol manufacturer, Kenvue, suddenly returned back before the opening bell one day after President Donald Trump promoted not the cases and in some cases links between tylenol, vaccines and autism.
“Do not take Tylenol,” asked Trump pregnant women around a dozen times at the White House press conference on Monday, also urging mothers not to give their infants the medicine, known as acetaminophen in the United States or paracetamol in most other countries.
The actions of the company of New Jersey Consumer Brands fell 7.5% on Monday. Actions found most of these losses early Tuesday in the market prior to the market.
The announcement, which seemed to be based on existing studies rather than new important research, arrives as secretary of health and social services Robert F. Kennedy Jr., a vaccine skeptic, advances the Make America Healthy Again movement which has focused on what it considers potential causes of autism.
Kenvue has challenged any link between drugs and autism this week and warned that if pregnant mothers do not use tylenol in need, they could face a dangerous choice between suffering fevers or the use of risky alternatives.
Kenvue was transferred from Johnson & Johnson in 2023. Apart from Tylenol, the consumer health company manufactures dressings, listing and other household brands.
The investment research analyst Citi, Filippo Falorni, wrote that he saw a limited risk of new proceedings after Trump’s announcement, but that “there could be a risk for the consumption of Tylenol given the negative titles”.
The company has fought hundreds of proceedings related to the product and its alleged bonds with autism, but most were rejected.
The analyst provides for a positive reaction for Kenvue’s actions at the opening bell on Tuesday given the lack of new scientific evidence.
Kenvue Inc.’s shares, based in Summit, New Jersey, climbed almost 5% in the market prior to the market.
Originally published:
